Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1843 results
June 2020
-
Featured News
Pride @ Novartis 2020 – inspired to make a difference
Together in spirit. Find out how our associates all over the world are joining together to make a difference as we celebrate Pride 2020.
-
Media Release
Novartis provides update on FDA review of ofatumumab, a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
Basel, June 2, 2020 — Novartis today announced that it has received notice from the US Food and Drug Administration (FDA) that the agency has extended its review of the Supplemental Biologics… -
Media Release
AveXis Community Statement on the Global Managed Access Program for AVXS-101
Dear SMA community, In January we launched a global Managed Access Program (MAP) for Zolgensma® (onasemnogene abeparvovec). Under this program, we are making up to 100 doses available in 2020 to… -
Featured News
European Patient Innovation Summit publishes call for action to ensure greater patient involvement in digital health solution development
EPIS participants call for all stakeholders to ensure the patient voice is at the heart of the development of digital health solutions
May 2020
-
Media Release
Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery
More than half of patients with BRAF-mutated advanced melanoma taking Tafinlar + Mekinist were alive and free of a relapse at 5-years1 Study conclusions are drawn from the largest dataset and… -
Media Release
Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation
Piqray (alpelisib) in combination with fulvestrant will become first and only targeted treatment for advanced breast cancer patients whose tumors harbor a PIK3CA mutation in Europe Phase III… -
Media Release
Novartis data highlight benefit of early treatment initiation in patients with secondary progressive multiple sclerosis (SPMS)
Novartis presented a total of 34 abstracts at the Congress of the European Academy of Neurology (EAN), emphasizing its strong multiple sclerosis (MS) portfolio with 20 abstractsLong-term efficacy… -
Featured News
Novartis at ASCO
Latest oncology resources and news surrounding Novartis data featured at American Society of Clinical Oncology (ASCO)
-
Statement
Novartis update following WHO Solidarity trial announcement
-
Media Release
Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease
New MONALEESA-7 (M7) and MONALEESA-3 (M3) subgroup analysis to be presented during ASCO20 Virtual Scientific Program Subgroup analysis shows Kisqali plus endocrine therapy extended life… -
Media Release
Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS)
Rapid and profound depletion of B-cells contributed to a halt in disease activity in RMS patients1 A post hoc analysis showed 47.0% and 87.8% of patients treated with ofatumumab achieved no… -
Media Release
Novartis study reveals that migraine support in the workspace can significantly decrease the impact of the disease on affected employees
The patients that completed the Migraine Care pilot program reported over 50% reduction in migraine disability and a significant improvement in their patient activation measure after six months …
Pagination
- ‹ Previous page
- 1
- …
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- …
- 154
- › Next page
Test disclaimer...!!!